English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Many evidences suggest that atherosclerosis is an inflammatory disease and inflammatory markers can be an important prognostic factors in acute coronary syndrome. Hydroxymethylglutaryl (HMG-CoA) redu- ctase inhibitors (statins) have been shown anti-inflammatory property that are independent of lipid-lowering effects. We evaluated the effects of 2-month treatment with simvastatin (40 mg/d, n=20) on plasma levels of circulating high-sensitivity C-reactive protein (hsCRP), inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6), and adhesion molecules (p-selectin and monocyte chemotactic peptide (MCP)-1) with placebo group (n=20) in 40 normocholesterolemic patients (LDL<130 mg/dl) with acute coronary syndrome. Simvastatin therapy significantly reduced plasma levels of total cholesterol and LDL-cholesterol (p=0.05, p=0.02, respectively) compared with placebo group. Simvastatin therapy also significantly reduced plasma levels of hsCRP and IL-6 (p=0.03, p=0.03, respectively) compared with placebo group. But, the reduction of hsCRP and IL-6 levels with simvastatin was unrelated to the degree of LDL-cholesterol's reduction. The effect of simvastatin on the reduction of hsCRP and IL-6, but not on the other inflammatory cytokines and adhesion molecules, have potential implications in the management of acute coronary syndrome with normocholesterolemia.

Statin Reduces C-Reactive Protein and Interleukin-6 in Normocholesterolemic Patients with Acute Coronary Syndrome